These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Long-term subcutaneous injection of lipopolysaccharides and high-fat diet induced non-alcoholic fatty liver disease through IKKε/ NF-κB signaling. He Q; Zeng J; Yao K; Wang W; Wu Q; Tang R; Xia X; Zou X Biochem Biophys Res Commun; 2020 Nov; 532(3):362-369. PubMed ID: 32883523 [TBL] [Abstract][Full Text] [Related]
27. Nutrigenomics analysis reveals that copper deficiency and dietary sucrose up-regulate inflammation, fibrosis and lipogenic pathways in a mature rat model of nonalcoholic fatty liver disease. Tallino S; Duffy M; Ralle M; Cortés MP; Latorre M; Burkhead JL J Nutr Biochem; 2015 Oct; 26(10):996-1006. PubMed ID: 26033743 [TBL] [Abstract][Full Text] [Related]
28. Inhibition of EGFR attenuates fibrosis and stellate cell activation in diet-induced model of nonalcoholic fatty liver disease. Liang D; Chen H; Zhao L; Zhang W; Hu J; Liu Z; Zhong P; Wang W; Wang J; Liang G Biochim Biophys Acta Mol Basis Dis; 2018 Jan; 1864(1):133-142. PubMed ID: 29038049 [TBL] [Abstract][Full Text] [Related]
29. Imaging Fibrogenesis in a Diet-Induced Model of Nonalcoholic Steatohepatitis (NASH). Hartimath SV; Boominathan R; Soh V; Cheng P; Deng X; Chong YC; Yong FF; Tan PW; Han W; Robins EG; Goggi JL Contrast Media Mol Imaging; 2019; 2019():6298128. PubMed ID: 31866798 [TBL] [Abstract][Full Text] [Related]
30. Geranylgeranyl diphosphate synthase (GGPPS) regulates non-alcoholic fatty liver disease (NAFLD)-fibrosis progression by determining hepatic glucose/fatty acid preference under high-fat diet conditions. Liu J; Jiang S; Zhao Y; Sun Q; Zhang J; Shen D; Wu J; Shen N; Fu X; Sun X; Yu D; Chen J; He J; Shi T; Ding Y; Fang L; Xue B; Li C J Pathol; 2018 Nov; 246(3):277-288. PubMed ID: 29971772 [TBL] [Abstract][Full Text] [Related]
31. Identification of genes in hepatocellular carcinoma induced by non-alcoholic fatty liver disease. Cai C; Song X; Yu C Cancer Biomark; 2020; 29(1):69-78. PubMed ID: 32623384 [TBL] [Abstract][Full Text] [Related]
32. Molecular profiling of nonalcoholic fatty liver disease-associated hepatocellular carcinoma using SB transposon mutagenesis. Kodama T; Yi J; Newberg JY; Tien JC; Wu H; Finegold MJ; Kodama M; Wei Z; Tamura T; Takehara T; Johnson RL; Jenkins NA; Copeland NG Proc Natl Acad Sci U S A; 2018 Oct; 115(44):E10417-E10426. PubMed ID: 30327349 [TBL] [Abstract][Full Text] [Related]
33. Integrative transcriptomic analysis of NAFLD animal model reveals dysregulated genes and pathways in metabolism. Yang W; He Y; Liu S; Gan L; Zhang Z; Wang J; Liang J; Dong Y; Wang Q; Hou Z; Yang L Gene; 2016 Dec; 595(1):99-108. PubMed ID: 27697615 [TBL] [Abstract][Full Text] [Related]
34. Expression of Vsig4 attenuates macrophage-mediated hepatic inflammation and fibrosis in high fat diet (HFD)-induced mice. Li Y; Sun JP; Wang J; Lu WH; Xie LY; Lv J; Li HX; Yang SF Biochem Biophys Res Commun; 2019 Aug; 516(3):858-865. PubMed ID: 31266632 [TBL] [Abstract][Full Text] [Related]
35. Agonist of RORA Attenuates Nonalcoholic Fatty Liver Progression in Mice via Up-regulation of MicroRNA 122. Chai C; Cox B; Yaish D; Gross D; Rosenberg N; Amblard F; Shemuelian Z; Gefen M; Korach A; Tirosh O; Lanton T; Link H; Tam J; Permyakova A; Ozhan G; Citrin J; Liao H; Tannous M; Hahn M; Axelrod J; Arretxe E; Alonso C; Martinez-Arranz I; Betés PO; Safadi R; Salhab A; Amer J; Tber Z; Mengshetti S; Giladi H; Schinazi RF; Galun E Gastroenterology; 2020 Sep; 159(3):999-1014.e9. PubMed ID: 32450149 [TBL] [Abstract][Full Text] [Related]
36. Integrated expression profiles of mRNA and miRNA in a gerbil model of fatty liver fibrosis treated with exenatide. Liu Y; Wu H; Wang Z; Wu J; Ying S; Huang M; Li Y Clin Res Hepatol Gastroenterol; 2021 Mar; 45(2):101312. PubMed ID: 33592427 [TBL] [Abstract][Full Text] [Related]
37. An Obesogenic Dietary Mouse Model of Nonalcoholic Steatohepatitis. Zarrouki B; Boucher J Methods Mol Biol; 2020; 2164():121-127. PubMed ID: 32607889 [TBL] [Abstract][Full Text] [Related]
38. Models of nonalcoholic steatohepatitis potentiated by chemical inducers leading to hepatocellular carcinoma. Márquez-Quiroga LV; Arellanes-Robledo J; Vásquez-Garzón VR; Villa-Treviño S; Muriel P Biochem Pharmacol; 2022 Jan; 195():114845. PubMed ID: 34801522 [TBL] [Abstract][Full Text] [Related]
39. Key features of the environment promoting liver cancer in the absence of cirrhosis. Zaki MYW; Mahdi AK; Patman GL; Whitehead A; Maurício JP; McCain MV; Televantou D; Abou-Beih S; Ramon-Gil E; Watson R; Cox C; Leslie J; Wilson C; Govaere O; Lunec J; Mann DA; Nakjang S; Oakley F; Shukla R; Anstee QM; Tiniakos D; Reeves HL Sci Rep; 2021 Aug; 11(1):16727. PubMed ID: 34408183 [TBL] [Abstract][Full Text] [Related]
40. The Angiogenesis Inhibitor ALS-L1023 from Lemon-Balm Leaves Attenuates High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease through Regulating the Visceral Adipose-Tissue Function. Kim J; Lee H; Lim J; Oh J; Shin SS; Yoon M Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28420164 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]